At the news
? BULLISHIMPACT 8/10 PRESS-RELEASE filed Jun 12, 2026 at 08:30 ET
Disc Medicine announced updated Phase 2 data for DISC-0974 in myelofibrosis anemia (55% major response in non-transfusion-dependent patients, 64% transfusion independence in low-burden TD) and sustained bitopertin PPIX reductions in EPP at EHA 2026. The company confirmed a Type A meeting with FDA where APOLLO Phase 3 data, due Q4 2026, can serve as basis for a CRL response and potentially support traditional approval. Initial DISC-3405 data in polycythemia vera also expected Q4 2026.
- Phase 2 RALLY-MF: 55% of nTD patients achieved hemoglobin increase ≥1.5 g/dL for ≥12 weeks (major response)
- 64% of TD Low and 50% of TD High MF patients achieved transfusion independence over 12-16 weeks
- 56% of JAK inhibitor-concomitant patients achieved major hematologic response across transfusion groups
- HELIOS OLE: Sustained PPIX reductions and improved light tolerance with up to 2.5+ years bitopertin exposure
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access